Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

CStone to Begin Australian Trials of Solid Tumor Cancer Drug

publication date: Aug 23, 2019

Suzhou's CStone Pharma has been approved to start an Australian Phase I clinical trial of its CDK4/6 inhibitor as a treatment for solid tumor cancers. CS3002 is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6), a mechanism that is thought to induce the cell cycle arrest of tumor cells. CStone said preclinical tests have shown CS3002 to have potential efficacy in combination with endocrine therapy or immune checkpoint inhibitor therapies. The company expects to start a Phase I trial of the candidate in China before the end of 2019. More details....

Stock Symbol: (HK: 2616)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.